Objective: MicroRNAs (miRs) are short noncoding RNA molecules that posttranscriptionally modulate protein expression. There are distinct miR alterations characterizing urothelial cell carcinoma (UCC) of the urinary bladder. Study Design: In this study, we investigate the possibility of using miR as a noninvasive marker in the screening of UCC. The total RNA was extracted from 75 cytology specimens including bladder or renal washings and voided urines. Cases comprise UCC (21 high grade and 6 low grade), 25 normal controls and 23 cases with a history of UCC but negative at the time of testing (negative with a positive history). The expressions of miR-96, miR-182, miR-183, miR-200c, miR-21, miR-141 and miR-30b were determined using quantitative TaqMan real-time PCR. Results and Conclusion: This study shows that the level of miR-182 is higher in cytology specimens from high-grade UCC patients as compared to normal controls. Measuring miR-182 may provide a potential alternative or adjunct approach for screening high-grade UCC.

Keywords:
Urothelial cell carcinoma, MicroRNA, miR-182, Diagnosis
1.
Roupret M, Zigeuner R, Palou J, et al: European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 59:584-594.
2.
Chapple CR, Steers WD (eds): Practical Urology: Essential Principles and Practice, ed 1. Springer Specialist Surgery Series. London, Springer, 2011.
3.
Luo B, Li W, Deng CH, et al: Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma. Cancer Genet Cytogenet 2009;189:93-97.
4.
Cibas ES, Ducatman BS: Cytology: Diagnostic Principles and Clinical Correlates, ed 3. Philadelphia, Saunders, 2009.
5.
Catto JW, Miah S, Owen HC, et al: Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 2009;69:8472-8481.
6.
Snowdon J, Boag S, Feilotter H, et al: A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J 2013;7:28-32.
7.
Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-1448.
8.
Wszolek MF, Rieger-Christ KM, Kenney PA, et al: A microRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol 2011;29:794-801.
9.
Han Y, Chen J, Zhao X, et al: MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 2011;6:e18286.
10.
Miah S, Dudziec E, Drayton RM, et al: An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 2012;107:123-128.
11.
Yamada Y, Enokida H, Kojima S, et al: miR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011;102:522-529.
12.
Hanke M, Hoefig K, Merz H, et al: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010;28:655-661.
13.
Valadi H, Ekstrom K, Bossios A, et al: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-659.
14.
Pignot G, Cizeron-Clairac G, Vacher S, et al: MicroRNA expression profile in a large series of bladder tumors: identification of a 3- miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 2013;132:2479-2491.
15.
Chiang CH, Hou MF, Hung WC: Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys Acta 2013;1830:3067-3076.
16.
Moskwa P, Buffa FM, Pan Y, et al: miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011;41:210-220.
17.
Hirata H, Ueno K, Shahryari V, et al: Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PloS One 2012;7:e51056.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.